Open Access



Main Article Content

Viktor Ivanovitch Goudochnikov corresponding author


A mini-review is presented for the evidence of growth-inhibitory effects of several psychoneurotropic drugs and glucocorticoids on developing animals and humans, together with our own data obtained in experimental models, as well as in epidemiologic studies confirming female predominance in morbidity caused by affective disorders and in consumption of some psychoneurotropic drugs. The emerging concepts of pharmacotoxicologic programming/imprinting and embedding are discussed, justifying the necessity of regional DOHaD centers.

anticonvulsive drugs, benzodiazepines, glucocorticoids, ontogeny

Article Details

How to Cite
Goudochnikov, V. (2019). The necessity of regional DOHaD centers based on programming/imprinting and embedding-like phenomena. Advances in Health and Behavior, 2(1), 30-33.


  1. Gluckman PD, Hanson MA, Buklijas T. A conceptual framework for the developmental origins of health and disease. Journal of Developmental Origins of Health and Disease, 2010, 1(1): 6-18.
  3. Harris A and Seckl J. Glucocorticoids, prenatal stress and the programming of disease. Hormones and Behavior, 2011, 59(3): 279-289.
  5. Costa LG, Steardo L and Cuomo V. Structural effects and neurofunctional sequelae of developmental exposure to psychotherapeutic drugs: Experimental and clinical aspects. Pharmacological Reviews, 2004, 56(1): 103-147.
  7. Thompson BL, Levitt P and Stanwood GD. Prenatal exposure to drugs: Effects on brain development and implications for policy and education. Nature Reviews Neuroscience, 2009, 10(4): 303-312.
  9. Williams JHG and Ross L. Consequences of prenatal toxin exposure for mental health in children and adolescents: a systematic review. European Child and Adolescent Psychiatry, 2007, 16(4): 243-253.
  11. Dodson WE. Deleterious effects of drugs on the developing nervous system. Clinics in Perinatology, 1989, 16(2): 339-360.
  13. Mantovani A and Calamandrei G. Delayed developmental effects following prenatal exposure to drugs. Current Pharmaceutical Design, 2001, 7(9): 859-880.
  15. Schain RJ and Watanabe K. Origin of brain growth retardation in young rats treated with phenobarbital. Experimental Neurology, 1976, 50(3): 806-809.
  17. Diaz J, Schain RJ and Bailey BG. Phenobarbital-induced brain growth retardation in artificially reared rat pups. Biology of Neonate, 1977, 32(1-2): 77-82.
  19. Gupta C, Sonawane BR, Yaffe SJ, et al. Phenobarbital exposure in utero: Alterations on female reproductive function in rats. Science, 1980, 208(4443): 508-510.
  21. Patsalos PN and Wiggins RC. Brain maturation following administration of phenobarbital, phenytoin, and sodium valproate to developing rats or to their dams: Effects on synthesis of brain myelin and other subcellular membrane proteins. Journal of Neurochemistry, 1982, 39(4): 915-923.
  23. Diaz J. Disruption of the brain growth spurt in adolescent rats by chronic phenobarbital administration. Experimental Neurology, 1983, 79(2): 550-563.
  25. Vasconcelos AP, Boyet S and Nehlig A. Consequences of chronic phenobarbital treatment on local cerebral glucose utilization in the developing rat. Developmental Brain Research, 1990, 53(2): 168-178.
  27. Vorhees CV. Fetal anticonvulsant syndrome in rats: Dose- and period-response relationships of prenatal diphenylhydantoin, trimethadione and phenobarbital exposure on the structural and functional development of the offspring. Journal of Pharmacology and Experimental Therapeutics, 1983, 227(2): 274-287.
  28. Van der Pol MC, Hadders-Algra M, Huisjes HJ, et al. Antiepileptic medication in pregnancy: Late effects on the children’s central nervous system development. American Journal of Obstetrics and Gynecology, 1991, 164(1): 121-128.
  30. Dessens AB, Cohen-Kettenis PT, Mellenbergh GJ, et al. Association of prenatal phenobarbital and phenytoin exposure with small head size at birth and with learning problems. Acta Paediatrica, 2000, 89(5): 533-541.
  32. Zala SM and Penn DJ. Abnormal behaviours induced by chemical pollution: A review of the evidence and new challenges. Animal Behaviour, 2004, 68(4): 649-664.
  34. Goudochnikov VI. Role of thyroid hormones and iodine consumption in the ontopathogeny of various diseases: Focus on interactions with glucocorticoids and some endocrine disruptors. Clinical and Experimental Thyroidology, Moscow, Russian, 2016, 12(1): 16-21.
  36. Schettler T. Toxic threats to neurologic development of children. Environmental Health Perspectives, 2001, 109(suppl.6): 813-816.
  38. Rodier PM. Environmental causes of central nervous system maldevelopment. Pediatrics, 2004, 113(4): 1076-1083.
  39. Hill LM and Kleinberg F. Effects of drugs and chemicals on the fetus and newborn (second of two parts). Mayo Clinic Proceedings, 1984, 59(11): 755-765.
  41. Dorman DC, Allen SL, Byczkowski JZ, et al. Methods to identify and characterize developmental neurotoxicity for human health risk assessment. III. Pharmacokinetic and pharmacodynamics considerations. Environmental Health Perspectives, 2001, 109(Suppl.1): 101-111.
  43. Simar MR. Perinatal exposure to CNS-active medications: neurodevelopmental risks. CNS Drugs, 1999, 12(6): 451-470.
  45. Fournier T, Mejdoubi N, Monnet D, et al. Phenobarbital induction of alpha1-acid glycoprotein in primary rat hepatocyte cultures. Hepatology, 1994, 20(6): 1584-1588.
  47. Agrawal AK, Pampori NA and Shapiro BH. Neonatal phenobarbital-induced defects in age- and sex-specific growth hormone profiles regulating monooxygenases. American Journal of Physiology, 1995, 268(3): E439-E445.
  49. Wilson MA, Biscardi R, Smith MD, et al. Effects of benzodiazepine agonist exposure on corticotropin-releasing factor content and hormonal stress responses: Divergent responses in male and ovariectomized female rats. Journal of Pharmacology and Experimental Therapeutics, 1996, 278(3): 1073-1082.
  50. Hirai M and Ichikawa M. Changes in serum glucocorticoid levels and thymic atrophy induced by phenytoin administration in mice. Toxicology Letters, 1991, 56(1-2): 1-6.
  52. Gudoshnikov VI, Fedotov VP. The heightened sensitivity of hypophyseal cells of neonatal rats to corticosteroids. Neuroscience and Behavioral Physiology, 1993, 23(2): 107-111.
  54. Goudochnikov VI. Pathogeny of glucocorticoid-induced growth retardation evaluated in experimental studies using laboratory animals and cell cultures as the models. NewsLab (Sao Paulo), Portuguese, 1997, 22: 90-100.
  55. Goudochnikov VI, Weber C, Silva CEJ, et al. The absence of diazepam interactions with inhibitory corticoid effects on body and target organ growth in young rats. Revista Contexto Saude (Ijui), Portuguese, 2003, 2(4): 103-104.
  56. Pawlikowski M, Stepien H, Mroz-Wasilewska Z, et al. Effects of diazepam on cell proliferation in cerebral cortex, anterior pituitary and thymus of developing rats. Life Sciences, 1987, 40(11): 1131-1135.
  58. Kunert-Radek J, Stepien H and Pawlikowski M. Inhibition of rat pituitary tumor cell proliferation by benzodiazepines in vitro. Neuroendocrinology, 1994, 59(1): 92-96.
  60. Goudochnikov VI and Weber C. Combined action of glucocorticoid and benzodiazepine on water content in target organs of rats. Revista Brasileira de Ciencias Farmaceuticas, 2005, 41: 231.
  61. Selye H, Prioreschi P and Jean P. Water fixation as the ultimate cause of tissue growth. Growth, 1959, 23: 169-187.
  62. Schliess F and Haussinger D. The cellular hydration state: a critical determinant for cell death and survival. Biological Chemistry, 2002, 383(3-4): 577-583.
  64. Haussinger D. The role of cellular hydration in the regulation of cell function. Biochemical Journal, 1996, 313(3): 697-710.
  66. Bayliss H, Churchill D, Beevers M, et al. Anti-hypertensive drugs in pregnancy and fetal growth: evidence for “pharmacological programming” in the first trimester? Hypertension in Pregnancy, 2002, 21(2): 161-174.
  68. Goudochnikov VI and Petersen R. Gender differences in psychotropic drug consumption may indicate enhanced risk of pharmacotoxicologic programming in perinatal period. Journal of Developmental Origins of Health and Disease, 2009, 1: S332-S333.
  69. Goudochnikov VI. Emerging terms and concepts of pharmacotoxicologic programming / imprinting and embedding, as related to the ontopathogeny of respiratory and other disorders. EC Pulmonology and Respiratory Medicine, 2018, 7(6): 413-415.
  70. Prokhorov LY and Goudochnikov VI. Role of glucocorticoids and stress in bioregulation of redox homeostasis in development and aging. Clinical Gerontology (Moscow, Russian), 2015, 21(11-12): 101-102.
  71. Goudochnikov VI and Prokhorov LY. Ontogenetic role of somatolactogens and related peptides as antistress hormones. Gerontologiya (Moscow), 2014, 2(2): 143-156.
  72. Prokhorov LY and Goudochnikov VI. Ontogenetic role of melatonin and neuroactive steroids as antistress hormones. Gerontologiya (Moscow), 2014, 2(2): 157-170.
  73. Mazaira S. Effects of psychiatric drugs on the fetus and newborn: Consequences of the treatment of psychiatric disorders during pregnancy and lactation. Vertex (Buenos Aires), Spanish, 2005, 16(59): 35-42.
  74. Bonari L, Pinto N, Ahn E, et al. Perinatal risks of untreated depression during pregnancy. Canadian Journal of Psychiatry, 2004, 49(11): 726-735.
  76. Sharma RR. Pregnancy, epilepsy and pharmacotherapy. Journal of Postgraduate Medicine, 1987, 33(4): 163-177.
  77. Camargo GN, Hirdes A and Goudochnikov VI. Expert committee on psychopharmacology: An ongoing experience in Brazil. International Journal of Psychosocial Rehabilitation, 2004, 9: 5-9.
  78. Goudochnikov VI. Gender differences in consumption of benzodiazepines by human population and in their effects on mice and rats. World Journal of Biological Psychiatry, 2007, 8: 200.
  79. Goudochnikov VI. Pharmacoepidemiology and drug surveillance in collective health], in Coletanea da Saude / Saude Coletiva: Dialogos Contemporaneos. Unijui, Ijui, Portuguese, 2006: 183-191.
  80. Benesova O, Tejkalova H, Kristofikova Z, et al. Early postnatal diazepam treatment of rats and neuroimmunocompetence in adulhood and senescence. Annals of New York Academy of Sciences, 1994, 717: 89-101.